The EBMT Complications and Quality of Life Working Party has developed a computer-based algorithm, the 'eGVHD App', using a user-centered design process. Accuracy was tested using a quasi-experimental crossover design with four expert-reviewed case vignettes in a convenience sample of 28 clinical professionals. Perceived usefulness was evaluated by the technology acceptance model (TAM) and User satisfaction by the Post-Study System Usability Questionnaire (PSSUQ). User experience was positive, with a median of 6 TAM points (interquartile range: 1) and beneficial median total, and subscale PSSUQ scores. The initial standard practice assessment of the vignettes yielded 65% correct results for diagnosis and 45% for scoring. The 'eGVHD App' significantly increased diagnostic and scoring accuracy to 93% (+28%) and 88% (+43%), respectively (both P o0.05). The same trend was observed in the repeated analysis of case 2: accuracy improved by using the App (+31% for diagnosis and +39% for scoring), whereas performance tended to decrease once the App was taken away. The 'eGVHD App' could dramatically improve the quality of care and research as it increased the performance of the whole user group by about 30% at the first assessment and showed a trend for improvement of individual performance on repeated case evaluation.
INTRODUCTION
The recently updated NIH criteria for chronic GvHD consolidate the standardization of diagnosis and scoring of GvHD through an international effort. 1, 2 The EBMT Complications and Quality of Life Working Party considers the use of these criteria a priority for clinical practice and research. As all GvHD registry data rely on centers' self-reporting, an accurate diagnosis and score is of paramount importance to correctly evaluate transplant outcomes. Unfortunately, the dissemination and implementation of NIH GvHD criteria is often considered challenging by clinicians, due to perceived complexity and time investment issues, limiting the use of the NIH criteria in daily clinical practice. 3 The EBMT Complications and Quality of Life Working Party therefore developed a computer-/web-based algorithm-driven application, the EBMT 'eGVHD App', to help clinicians diagnose and score the severity of GvHD faster and more accurately. We applied a user-centered design process, 4 which implies an assessment of need for the tool and evaluation of its anticipated features, followed by an iterative process of design, end-user feedback and modification to ensure that the App is user-friendly and efficiently serves its purpose. Here we describe the development of the 'eGVHD App' according to user-centered design principles and its preliminary usability testing, and compare its accuracy against 'standard practice' (that is, using the NIH GvHD guidelines on paper) using validated cases as the gold standard.
METHODS

User-centered design-based development
A team of information technology experts, usability experts and GvHD experts was put together to draft a prototype of the App on paper. After iterative discussions, the first version of the 'eGVHD App' (v0.0) was designed as two screens with a list of GvHD-related signs and symptoms scored as 'present/not present'. An algorithm-based diagnosis and score was generated according to the NIH criteria.
1,2 v0.0 was tested in an iterative process including clinical staff and GvHD experts. Several issues were identified and resolved (for example, errors in the algorithm, oversimplification of terms and rigid technical limitations), resulting in an improved prototype v1.0, which became a true web application (App), compatible with desktop computers and smartphones/tablets. In addition, v1.0 included a succession of screens (one per organ) to allow for a clearer layout, a more detailed description of the signs and symptoms, and the opportunity to use complex technical coding methods to reflect the NIH criteria more accurately.
More specifically, v1.0 relies on two modules. The diagnostic module reviews 10 different organ systems (skin, nails, scalp/body hair, mouth, eyes, genitals, gastrointestinal tract, liver, lungs and muscles/joints) for diagnostic, distinctive, common signs or proven evidence of GvHD. The scoring module is used to assess severity. For acute GvHD scoring, four levels of severity over three organ systems (skin, gastrointestinal and liver) are scored, yielding a Glucksberg score (ranging from I to IV) and IBMTR score (ranging from A to D). 5 For chronic and overlap GvHD severity scoring, four levels of symptoms (0-3) for eight organs (skin, mouth, eyes, gastrointestinal, liver, lungs, muscles and genitals) are scored, resulting in an overall mild, moderate or severe score according to the NIH criteria. 1, 2 Accuracy testing v1.0
We tested the accuracy of version v1.0 using a quasi-experimental crossover design with four case studies in a convenience sample of clinical professionals working at the Hematology Department of the University Hospitals of Leuven, Belgium (Figure 1 ). Four clinical vignettes reflecting classic acute GvHD, overlap chronic GvHD, late acute GvHD and classic chronic GvHD were developed and reviewed by a panel of three international GvHD experts, to serve as gold standard for accuracy testing. We assigned professionals, clustered by profession and seniority, to either group A or group B as a function of their arrival in the test room. Professionals were invited to solve clinical cases 1 and 2 either using exclusively standard paper forms (group A) or using the 'eGVHD App' (group B) on a desktop computer. Then, the groups crossed over as follows: group A gave back the paper forms and received the App to solve clinical cases 1 and 2 again, as well as cases 3 and 4 for the first time. Group B did the same thing, but this time with paper guidelines instead of using the App.
Usability testing v1.0
Perceived usefulness was evaluated by the 'perceived usefulness' subscale of the technology acceptance model at baseline and end of study. This validated self-report scale consists of six statements, referring to the extent to which the user believes the technology will improve his work performance. Statements are rated on a 7-point Likert-like scale (1 = 'extremely unlikely' to 7 = 'extremely likely'). A median score was calculated for each item separately, with higher scores reflecting higher perceived usefulness. 6, 7 User satisfaction was evaluated by the Post-Study System Usability Questionnaire, a 19-item self-reporting instrument using 7-point Likert-like scales (1 = 'strongly agree' to 7 = 'strongly disagree'), with three subgroups reflecting system usefulness (items 1-8), information quality (items 9-15) and interface quality (items 16-18). Post-Study System Usability Questionnaire scores are represented as median total and subscale scores, with lower scores reflecting higher user satisfaction. 8 Open questions and oral feedback were used to identify potential for improvement
The accuracy of the App was evaluated by the proportion of correctly assessed clinical vignettes per group according to the gold standard set by international experts, excluding missing values. Case 1 (classic acute GvHD) was excluded due to technical problems. The accuracy of the first assessment of cases 2-4 was analyzed 'between groups' ('standard practice' versus 'using the App') and within groups A and B on the repeated assessment of case 2 ('standard practice', then 'using the App' in group A; 'using the App', then 'standard practice' in group B) using Fisher's exact test. 'Better', 'worse' or 'unchanged' individual performance at the reevaluation of case 2 was also reported.
RESULTS
Twenty-eight professionals participated: 8 senior physicians, 8 junior physicians, 2 medical students and 10 data managers/ research nurses, and were assigned to one of two groups (A or B), evenly distributed by profession and seniority. Median experience in hematology was 2.25 years (range 0-30; interquartile range 6.6).
User experience was positive, with a median of 6 technology acceptance model points (interquartile range: 1) for the majority of aspects analyzed (Table 1) . For questions relative to the effect of the App on job performance and productivity, the median score increased from 5.5 and 5, respectively, to 6, after using the App. User satisfaction (Table 1) was also high, as reflected by the beneficial median total and subscale Post-Study System Usability Questionnaire scores.
The initial assessment of clinical vignettes 2-4 ( Table 2 ) using standard paper tools yielded 65% correct results for diagnosis and 45% for scoring. The use of the App significantly increased diagnostic and scoring accuracy to 93% (+28%) and 88% (+43%), respectively (both P o 0.05). The effect of the App on diagnosis and scoring accuracy was similar between data managers and physicians (+23% and +31% accuracy for diagnosis and +53% and +37% for scoring, respectively), yet the small numbers preclude statistical comparison.
The same trend was observed at a group level in the repeated analysis of case 2: the accuracy of group A improved by repeating the same case using the App (+31% for diagnosis and +39% for scoring), whereas the performance of group B tended to decrease once the App was taken away. At the individual level, more professionals tended to correct their diagnosis/score when given the App compared with professionals repeating the case with paper guidelines only.
Based on hurdles identified during the usability testing, the EBMT 'eGVHD App' v2.0 has been developed refining details in the algorithm, improving term description, and adding a user's manual and the option of generating patient reports. Testing of v2.0 is currently underway to adapt layout and screen content and to address the ambiguities of current guidelines.
DISCUSSION
The EBMT Complications and Quality of Life Working Party has applied a rigorous user-centered design approach to generate the first academically developed electronic tool available to date to reliably diagnose and score GvHD. The 'eGVHD App' is now ubiquitously accessible on electronic platforms, performs accurately to reflect the subtle nuances of the revised NIH criteria and shows promising results in initial testing. By incorporating several rounds of user feedback during the development process of the App, we achieved high results for both user-perceived usefulness and satisfaction, suggesting that the tool is userfriendly and intuitive. Post-study system usability questionnaire (PSSUQ) Figure 1 . Study design.
Development, preliminary usability and accuracy testing of 'eGVHD App' H Schoemans et al Furthermore, we showed that the use of the App results in a statistically significant improvement in GvHD assessment. The App increased GvHD diagnosis and scoring accuracy for the whole user group by about 30% at first assessment of the clinical vignettes. It showed a trend for improvement of individual performance on repeated case evaluation: about a third of professionals in group A were able to improve on their GvHD re-assessment of case 2 by using the App, whereas little improvement was seen in professionals of group B repeating the GvHD evaluation of case 2, using standard paper forms (two individuals actually failing to diagnose and score the vignette correctly once the App was taken away). This underlines the importance of the support offered by the App, beyond a potential 'learning effect' derived from the repetition of the assessment of case 2.
This work represents a proof of concept that an electronic tool is likely to improve GvHD assessment. However, there are obvious limitations to this study. First, the App was only evaluated in a single center, by a limited number of professionals in the artificial setting of case vignettes. Real-life testing in different settings still needs to be performed. Second, the relatively low number of participants and wide variation in stem cell transplantation experience did not allow us to investigate the impact of the App on the performance of different types of users in detail. Third, a technical problem in the classical acute GvH1D vignette precluded analysis of the impact of the App on assessment of acute GvHD. Finally and most importantly, further development of the App requires a systematic validation of the electronic decision algorithm to make sure the App gives correct diagnosis and score in virtually all circumstances. Such a validation is currently underway in collaboration with the National Cancer Institute in Bethesda, MD, USA, to confirm the accuracy of the computer algorithm and mode equivalence before further implementation is carried out.
The EBMT Complications and Quality of Life Working Party considers that the 'eGVHD App' has the potential to dramatically improve the quality of care as well as clinical research across transplant centers by supporting more accurate and reliable assessment of GvHD. Larger-scale accuracy testing and implementation is currently being planned in diverse settings to further evaluate the effectiveness and scalability.
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User experience-TAM Median score (IQR) (7 = extremely likely; 1 = extremely unlikely)
Using the 'EBMT GVHD app' would… Before using the app (N = 28) After using the app (N = 28) Enable me to accomplish tasks more quickly 6.0 (IQR: User satisfaction-PSSUQ Median score (IQR) (1 = strongly agree; 7 = strongly disagree)
After using the app (N = 28)
1. Overall, I am satisfied with how easy it is to use this system 2.0 (IQR: 1.0) 2. It was simple to use this system 3.0 (IQR: 1.0) 3. I could effectively complete the tasks and scenarios using this system 2.0 (IQR: 1.0) 4. I was able to complete the tasks and scenarios quickly using this system 3.0 (IQR: 1.0) 5. I was able to efficiently complete the tasks and scenarios quickly using this system 2.0 (IQR: 1.0) 6. I felt comfortable using this system 2.0 (IQR: 1.0) 7. It was easy to learn, use this system 1.5 (IQR: 1.0) 8. I believe, I could become productive quickly using this system 2.0 (IQR: 1.0) System use subscale score 2.0 (IQR: 0.6) 9. The system gave error messages that clearly told me how to fix problems 5.0 (IQR: 2.0) 10. Whenever I made a mistake using the system, I could recover easily and quickly Case 2 = 'overlap chronic GvHD' clinical vignette; Case 3 = 'late acute GvHD' clinical vignette; Case 4 = 'classic chronic GvHD clinical' vignette; better = diagnosis was wrong at the initial evaluation but right at the second evaluation of case 2; worse = diagnosis was initially right, but wrong at the second evaluation of case 2; unchanged = diagnosis remained right or wrong at both evaluations of case 2; *Po0.05.
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